Esperion Therapeutics announced that it has initiated a Phase 2 study for ETC-1002 for the treatment of patients with dyslipidemia. The 12-week, multi-site, randomized, double-blind, placebo controlled study will enroll 176 patients with hypercholesterolemia, with or without high triglycerides, to assess the role of ETC-1002 in lipid regulation (LDL-C and triglycerides).
ETC-1002 is a small molecule compound that has demonstrated preclinical and clinical activity as a metabolic regulator of imbalances in lipid and carbohydrate metabolism. The compound acts to inhibit fatty acid and cholesterol synthesis and enhance fatty acid oxidation. ETC-1002 has the potential to regulate LDL-C, HDL-C, triglycerides, glucose/insulin and other cardio-metabolic risk factors.
For more information call (734) 862-4840 or visit www.esperion.com.